Fluorescence in situ hybridization (FISH) analysis has shown previously that 10-15% of chronic myeloid leukemias (CML) have hemizygous deletions of variable sizes affecting regions that flank the ABL and BCR translocation breakpoints on the derivative chromosome 9, and these patients have a poor outcome. FISH studies using large commercial genomic probes have previously suggested that haploinsufficiency of sequences flanking either ABL or BCR modify the disease process of CML and lead to an unfavorable prognosis. In this present study, real-time quantitative PCR (Q-PCR) analysis was used to identify and map much smaller hemizygous microdeletions in a subset of CML patients that were not deleted using large genomic FISH probes. Microdeletions were identified by Q-PCR in 25 of 71 patients selected based on less favorable outcome (chronic phase duration of less than 96 months and a survival time of less than 84 months). In contrast, no microdeletion was detected in any of 18 CML samples selected from a group with a more favorable outcome. Detailed mapping of the 25 Q-PCR microdeletions showed that the minimal deleted region extended B120 kb from the 5 0 end of the ABL gene in the centromeric direction on the derivative chromosome 9, and the region 3 0 to BCR on chromosome 22 was excluded. Of the four ESTs and/or genes that map to the 120 kb region, the putative tumor suppressor PRDM12 is the strongest candidate gene. The potential role for each sequence in modifying the clinical behavior of CML is presented.
Introduction
Chronic myeloid leukemia (CML) is a clonal, hematologic malignant disease characterized by the acquisition of the BCR/ ABL fusion gene, which is usually generated by a cytogenetically balanced Philadelphia (Ph) chromosome translocation. The product of the BCR/ABL gene, the Bcr/Abl protein, is a constitutively active protein tyrosine kinase, which plays a central role in the pathogenesis of CML. The oncoprotein's major cellular effects relate to increased mitogenic activity, 1 reduced sensitivity to apoptosis, [2] [3] [4] and altered adhesion and homing of CML progenitor cells. [5] [6] [7] [8] [9] CML is characteristically triphasic, with a chronic phase, lasting 3-6 years, followed by a transformation to the accelerated and blast phases with a much shorter duration. [10] [11] [12] [13] [14] Patients with CML show considerable clinical heterogeneity in the duration of the chronic phase, as well as response to treatment and overall survival. Refinements in treatment for CML, such as interferon and bone marrow transplantation, have been implemented. These extraordinary advances in CML treatment and basic research culminated recently in promising clinical trials using Imatinib, which targets therapy to the specific molecular aberration in leukemic cells. 15 Unfortunately, the development of resistance to Imatinib is already a problem. This can be multifactorial 16, 17 and can include mechanisms such as BCR/ABL gene amplification, 16, 18, 19 development of multidrug resistance, 19 or mutation of the Bcr/ Abl kinase domain. 20 Despite intensive analysis of the cause of drug resistance, it is clear that not all Imatinib treatment failures can be accounted for by these changes. Therefore, understanding the molecular basis of differential prognosis is extremely important for the management of CML and for the better refinement of treatment.
It has been recently shown by fluorescence in situ hybridization (FISH) analysis that B10-15% of CML have hemizygous submicroscopic deletions of the reciprocal ABL/BCR region on the derivative chromosome 9 (der(9)), and that these patients often have a poor clinical response. [21] [22] [23] [24] [25] These studies have implied that haploinsufficiency of gene(s) mapping to a relatively large genomic region of B500 kb flanking the ABL/ BCR breakpoints on the der(9), may account for the differential prognosis in CML. However, one limitation of conventional FISH methodology is that the larger commercial FISH probes will not usually detect smaller, more localized hemizygous microdeletions closer to the reciprocal breakpoint region of ABL/BCR.
Real-time quantitative PCR (Q-PCR) methods have been widely used for identifying genomic copy number changes [26] [27] [28] [29] but have not previously been used to investigate microdeletions in the ABL/BCR region of the der (9) in CML. In this study, a series of 11 primer sets distributed across B442 kb of genomic DNA were used to determine the distribution and relative frequency of microdeletions in CML. The improved resolution of Q-PCR permitted a systematic analysis of the minimal deleted region immediately adjacent to the ABL/BCR breakpoint on the der (9) . The study group screened by Q-PCR comprised of 71 CML samples selected on the basis of adverse outcome (chronic phase duration of less than 96 months and a survival time of less than 84 months) and 18 CML samples in which outcome was favorable. In every case conventional FISH methods had been previously used to exclude the possibility that larger submicroscopic deletions of the der(9) were present in these samples. 22 This study showed that 25/71 patients with adverse outcome had a hemizygous microdeletion, but none of the 18 samples with a favorable response had a microdeletion. Mapping of the 25 Q-PCR microdeleted samples showed that the minimal deleted region extends B120 kb from the 5 0 end of the ABL gene in the centromeric direction on the der (9) . There are at least four candidate genes within this minimal deleted region, and the function of one of these genes (PRDM12), which has sequence homology with a tumor suppressor gene family, would be predicted to have a role in determining differential outcome in CML.
Materials and methods

Patient cohort and study design
Informed consent in accordance with the Helsinki protocol was obtained following the institutional guidelines for all patients. A total of 250 CML bone marrow samples were obtained for FISH, cytogenetics and molecular studies as part of the routine laboratory service studies of these patients. It has been previously shown 22 that of the 250 CML samples, 23 had a submicroscopic deletion detectable by FISH. Of these, 19 had a standard Ph translocation with gross deletions (4500 kb) on the der(9), and a further four patients had a complex Ph translocation associated with a submicroscopic FISH deletion. From the remaining 227 patients without a gross FISH deletion, a subgroup of patients exhibiting poor response was selected for detailed Q-PCR analysis. Since our previous study determined that CML patients without a FISH deletion exhibited a median duration of the chronic phase of 96 months and a survival time of 84 months, 22 we selected these outcome measures to evaluate the 227 patients clinical responses. Of the 227 patients, 71 patients satisfied these inclusion criteria and had duration of the chronic phase and a survival time of less than each of these respective outcome medians. A representative subset of 18 patients with more favorable chronic durations and survival times was also included, so that the study group comprised a total of 89 CML samples. All bone marrow samples had a minimum of 55% Ph-positive cells, as determined by conventional cytogenetic analysis and/or interphase FISH studies. Interphase FISH provides a more exact quantification of the relative proportion of Ph-positive cells, and thus was used to assess normal cell contamination in the majority of cases. Owing to the retrospective nature of this study, it was not possible to obtain interphase quantitation in a small proportion (four samples) of cases. From the 71 CML samples in the subgroup, DNA was available for 53 patients, RNA from 20 patients and fixed cytogenetic suspensions from 20 patients. For six CML patients, both DNA and RNA were available, and for five patients both DNA and cytogenetic suspension were available. In only one CML sample was it possible to perform assays based on all three methodologies.
Real-time Q-PCR analysis of DNA Q-PCR was performed to detect hemizygous genomic deletions based on fluorescent SYBR Green I dye methodology. [30] [31] [32] The kinetics of Q-PCR uses standard PCR in conjunction with a fluorescent method (SYBR Green I assay) and an ABI Prism 7700 Sequence Detector, which is capable of measuring fluorescence in real time. 27, [33] [34] [35] [36] [37] The number of cycles required for reporter dye fluorescence to exceed background level was defined as the Table 1 Primer sequences used for Q-PCR scanning and mapping assays Primers for mapping assay Chromosome 9 side, centromere direction PRDM12
Primers for reference genes RPS9
Identification of minimal deleted region by QPCR E Kolomietz et al cycle threshold (C T ) and was automatically estimated using the ABI PRISM s 7700 Sequence Detection System (PE Applied Biosystems, Foster City, CA, USA). Genomic DNA was extracted using the Qiaamp DNA blood kit (Qiagen, Valencia, CA, USA). Control DNA included seven patients with large hemizygous deletions (one copy) that were previously identified by FISH methods 22 and five normal DNA samples (ie a two copy number control). In addition, a normal DNA calibrator sample was analyzed on every assay plate, together with the CML DNA samples of interest. On chromosome 9, the first set of primers was designed using the genomic sequence for the ABL gene exon 1b and on chromosome 22 the first set of primers was designed using the genomic sequence for the BCR gene exon 17, avoiding repetitive sequences. The 11 consecutive primer sets used for microdeletion analysis were designed using genomic sequences 5 0 of ABL, exon 1b, and 3 0 of BCR, exon 17 ( Table 1 ). The selection of primer sequences was performed using the ABI Primer Express Software (version 1.5), based on optimal conditions for real-time PCR primer design. All primers were purchased from AGCT Inc. (Toronto, ON, Canada). Three sequences 38 were chosen to serve as controls for copy number determinations on other chromosomes: GAPDH (chromosome 12p13), RPS9-Ribosomal protein 9 (chromosome 19q13.4) and YWHAZ-Phospholipase A2 (chromosome 2p25.2). For each new set of primers for the target sequence, primer validation experiments with all three reference sequences were performed. 39 Only reference sequences that demonstrated equal efficiency of the PCR reaction at the chosen dilution levels were used for the assay. Initial PCR optimizations were carried out to determine the concentration of primer and template required to produce the highest intensity and specificity of SYBR Green fluorescence. In each 96-well assay, up to 14 patients, one normal calibrator control, and a 'no-template' control were included. Each sample was run in triplicate for both target and reference sequences. A PCR master mix was aliquoted to a final volume of 25 ml and consisted of: 12.5 ml of 2 Â SYBR Green s PCR Master Mix (Applied Biosystems, Foster City, CA, USA), 400 nM forward primer, 400 nM reverse primer and 20 ng of template DNA. Thermal cycling conditions comprised 501C for 2 min, 941C for 10 min, and 40 cycles at 951C for 15 s followed by 601C for 1 min. The relative copy number of target sequences in DNA samples was determined using a comparative C T (DDC T ) method. 40 This method calculates a relative value both to the normal control DNA (the calibrator) and to the endogenous control reference sequence. The starting relative copy number of the target tumor DNA is given by 2 -DDCT , where
We have developed freely available software for copy number determinations using the DDC T method. The program 'Ct_Ana-lysis' can be found at http://www.utoronto.ca/cancyto/ LEU2003/.
Detection of microdeletions in DNA derived from CML samples containing normal cells
The majority of patients studied had 495% of leukemic cells in their bone marrow aspirates. In five samples normal cell contamination of 15-40% was present, therefore, a sensitivity assay was established to determine the sensitivity of Q-PCR for detecting hemizygous deletions when both normal and leukemic cells were present in the bone marrow aspirate. In these experiments, a dilution series was established utilizing DNA from a FISH-verified deletion sample that contained 490% of leukemic cells. The dilution series with normal DNA demonstrated that the dynamic range of Q-PCR was sufficient to detect microdeletions with all primer combinations when o50% of normal cell contamination was present ( Figure 1 ).
RT-PCR analysis of the ABL/BCR reciprocal transcript
RNA was isolated from bone marrow clinical samples using the RNeasy Mini Kit (Qiagen, Valencia, CA, USA). All RNA samples were demonstrated to be BCR/ABL-positive by standard RT-PCR methods. CML samples that were negative for the deletion by FISH were assessed for ABL/BCR expression using wellestablished RT-PCR methods as described previously. 41 The normal ABL gene is usually expressed in BCR/ABL-positive cells, 41, 42 therefore in all experiments, primers from ABL exons 1b and 3 were used. The ABL/BCR transcripts were amplified using oligonucleotides specific for the ABL alternative exons 1b and 1a, together with a reverse primer from exon 17 of the BCR gene in primer combinations ABL/BCR (1b-e17) and ABL/BCR (1a-e17), respectively. Amplification of specific sequences on the ABL and ABL/BCR genes were carried out by one-step RT-PCR (Titaniumt One-Step RT-PCR Kit, BD Biosciences, Clontech, Palo Alto, CA, USA). 43, 44 Reverse transcription was performed for 1 h at 501C. The subsequent thermal cycling conditions comprised of 941C for 5 min, and 35 cycles at 941C for 30 s followed by 621C for 30 s and 681C for 1 min. The sizes of the obtained bands were 585, 440 and 466 bp for exon junction 1b-e17 and 1a-e17 for ABL/BCR fusion gene and for ABL gene exon 1b, respectively.
FISH analysis using PCR probes from ABL and BCR
As a secondary method of confirming the presence of microdeletions, a subset of samples was studied by metaphase FISH 
Figure 1
Sensitivity assay used to demonstrate the ability of Q-PCR to detect CML deletions when a variable percentage of normal cell contamination is present in bone marrow samples. The proportion of normal cells present in any CML bone marrow sample may vary considerably, especially when samples are obtained from treated CML patients. To determine the sensitivity of Q-PCR for identification of deletions when mixed proportions of normal and deleted cells are present, a dilution series containing defined ratios of DNA derived from normal and deleted cell populations was established. The control-deleted sample used in this assay was a CML in which 90% of leukemic cells detected were shown to be deleted by FISH. These experiments showed that as much as 50% contamination with DNA derived from normal cells would not preclude recognition of a deletion by Q-PCR.
Identification of minimal deleted region by QPCR E Kolomietz et al analysis. To develop FISH probes from the regions containing microdeletion, long PCR products were generated using primers derived from the 5 0 ABL exon 1b, and 3 0 BCR exon 17 genomic regions (see Figure 2a for probe configuration). The selection of primer sequences for long template PCR was performed utilizing the ABI Primer Express Software (version 1.5), using optimal conditions for long PCR primer design. All primers were purchased from AGCT Inc. (Toronto, ON, Canada). The probe for chromosome 9, flanking the breakpoints of the ABL gene and extending in centromeric direction, consisted of two long PCR products with the interval between them being 872 bp. The first PCR product, which started 5 0 of exon 1b of the ABL gene, was 7068 bp long and was created by the primers 5 0 -ACACGAGGTGAACCCAGTAGGTAGATG and ATTATCAC-TATCTTACAGATGAGGAAACTGACCGT-3 0 . For the second PCR product, 7611 bp long, the primers were 5 0 -GCCATGGTT-CACCTTGATCTTCAGTC and AGAACTCGTCAGTGAAGAGG-3 0 . The probe for chromosome 22, flanking the breakpoints of the BCR gene and extending in the telomeric direction, also consisted of two long PCR products with the interval between them being 969 bp. The first PCR product, which started at exon 17 of the BCR gene, was 7187 bp long and was created by the primers 5 0 -TAGAACGTGCTCCCCATAA-AACGGG and CTTGACAAGTGATCCAGTAGAAATCTTTTA-GACTCT-3 0 For the second PCR product, 7611 bp long, the primers were 5 0 -GTATACCACACAGAGTCGCTTAGCCG and Identification of minimal deleted region by QPCR E Kolomietz et al AAGTACTCTCGGTTGCATCCTTCGG-3 0 . Long template PCR was performed using the Expand Long Template PCR System (Roche Molecular Biochemicals, Laval, Canada) in 50 ml reaction containing 500 mM dATP, 500 mM dTTP, 500 mM dCTP, 500 mM dGTP, 300 nM forward primer, 300 nM reverse primer, 10 Â PCR buffer with 22.5 mM MgCl 2 . The PCR reaction comprised of 2.5 U of Expand Long Template enzyme mixture and 500 ng of normal template DNA. PCR was performed according to the thermal profile: 2 min at 941C, and 10 cycles of 10 s at 941C, 30 s at 621C and 8 min at 681C followed by 20 cycles of 10 s at 941C, 30 s at 621C, 8 min +20 s/cycle at 681C, followed by a hold of 7 min at 681C. The long PCR products were labeled by incorporation of digoxigenin (for chromosome 22 sequencesFBCR gene, exon 17) and biotin (for chromosome 9 sequencesFABL gene, exon 1b) by nick translation. An equimolar mixture of each labeled probe at a concentration of 10 ng/ml was hybridized to CML cytogenetic preparations and control normal metaphase preparations, and detected with FITC-avidin and antidigoxigenin rhodamine. Both probes exhibited excellent hybridization efficiencies of 480%. All FISH images were captured and analyzed with the Vysis Quips Smart Capture Imaging System (Vysis, Downers Grove, IL, USA).
Sequence analysis within the minimal deleted region
Sequence data hosted by the NCBI and other public domain genomic databases [Genome database (http://www.gdb.org. Genome database), Genbank (http://www.ncbi.nlm.nih.gov/ Genbank. Genbank), the EMBL nucleotide sequence database (http://www.ebi.ac.uk/embl/. EMBL nucleotide sequence database), the DNA Database of Japan (http://www.ddbj.nig.ac.jp/. DNA Database of Japan) and Genecards (http://www.rigeb.-gov.tr:5000. Genecards. In)] were analyzed within the minimal deleted region to identify: (i) unique known genes (ii) unknown sequences with homology to known genes and (iii) unique unknown genes. Two approaches were undertaken for sequence analysis: comparison by similarity (homology), and analysis by intrinsic sequence properties. 45 The identity of all known genes or ESTs mapping to the minimal deleted region was determined. For gene prediction of unknown sequences, a combination of standard exon and gene finder softwares such as GRAIL (http:// compbio.ornl.gov/Grail-1.3. GRAIL), Genscan (http://genes.mit.edu/GENSCAN.html. Genscan. In), Genie (http://www.fruitfly.org/seq_tools/genie.html. Genie. In), GENOTATER (http:// www.fruitfly.org/Bnomi/genotator. GENOTATER. In) were used. Once provided with a 'significant' match, candidate genes and the predicted functions of encoded proteins were assessed. For newly discovered genes as well as for unknown sequences with homology to known genes, relevant information from DNA and protein sequence databases, gene function and phenotype databases (The TRANSFAC Database (http://bioinformatics.weizmann.ac.il/transfac/. The TRANSFAC Database), Genecards (http://www.rigeb.gov.tr:5000. Genecards. In), protein structure and motif databases (http://www.expasy.ch/tools/ scnpsit1.html. PROSITE, http://www.gsf.de/biodv/matinspector.html. MatInspector, http://www.blocks.fhcrc.org. BLOCKS, http://www.ncbi.nlm.nih.gov/Structure/cdd/wrpsb.cgi.
Conserved Domain Database Search, http://www.ncbi.nlm.nih.-gov/Structure/lexington/lexington.cgi?cmd ¼ rps.
DART: Domain Architecture Retrieval Tool, http://smart.embl-heidelberg.de/. SMART (Simple Modular Architecture Research Tool) were evaluated. Gene expression profiles of candidate genes were assessed by 'in silico' Northern expression and SAGE analysis (http://www.ncbi.nlm.nih.gov/SAGE/. SAGE-Serial Analysis of Gene Expression). These data provided insight into each gene's function, pattern of expression in tissues, protein structure type or class, functional family, metabolic role and potential relation to disease phenotypes. Candidate genes were then selected based on their functional involvement in cell cycle control, DNA repair, apoptosis, growth inhibition or expression in hematopoietic cells.
Results
RT-PCR analysis of ABL/BCR in CML
Expression of the ABL-1b alternative transcript from the normal ABL allele was observed in all 20 patient samples for which RNA was available. No ABL1a-BCR transcript was detected in any of the samples examined, suggesting that the majority of the breakpoints within the ABL gene might be located upstream of exon 1a. A total of 80% (16/ (Figure 3b ). In addition, the inferred, putative deletions predicted by failure to detect transcripts of ABL/BCR by RT-PCR analysis of RNA were found to be present in three of the four DNA samples. Thus, at the end of this component of the study, the 25 CML samples were found to contain a hemizygous microdeletion, and in all cases such deletions were only observed within the group of 71 CML patients with a less favorable treatment response. No such microdeletions were detected in the 18 CML samples obtained from patients with a more favorable response to treatment. The minimal region of hemizygosity within the 25 microdeletions comprised two classes: (1) hemizygous deletions involving just 5 0 ABL (nine patients); or (2) hemizygous deletions involving both 5 0 ABL and 3 0 BCR sequences (16 patients).
FISH confirmatory analysis using 5 0 ABL and 3 0 BCR FISH probes Microdeletions were also identified by FISH analysis. For these experiments, long PCR was used to generate B14 kb probes just 5 0 to ABL and 3 0 to BCR. Dual-color FISH analysis was performed on cytogenetic preparations derived from four CML patients without an apparent microdeletion as detected by (Figure 2b-e) .
Delineation of the minimal deleted region by Q-PCR
To determine the size of each submicroscopic genomic deletion in our 25 CML samples, we designed 11 primer sets every 20-50 kb, to provide uniform coverage of the 442 kb (Figure 4 Identification of minimal deleted region by QPCR E Kolomietz et al and the measurement was extended in the centromeric direction towards the ASS gene. Similarly for chromosome 22, Q-PCR was initiated from exon 17 of BCR gene in the telomeric direction towards IGLL. At every interval, the copy number of each DNA sample was determined. For all microdeletions, a copy number of one was identified by contiguous primer sets. When Q-PCR analysis of a flanking primer set provided a copy number of two, it was assumed that the hemizygous deletion border on the der(9) had been crossed. There were no examples of multiple deletions or complex rearrangements in which two separated or noncontiguous regions of deletion were detected. As shown in Figure 4 , all 25 hemizygous deletions were contiguous but of variable size. In summary, this subregional mapping indicated that the minimal deleted region was B120 kb 5 0 to ABL defined by the interval between PRDM12 and the ABL/BCR breakpoint region on the der(9) (Figure 4 ). The region 3 0 to BCR on the der(9) was excluded from consistent involvement in loss. Thus, the minimal deleted region based on these 25 CML samples is flanked distally by the marker SHGC-141674 and proximally by breakpoints on the ABL gene (the breakpoint in the ABL gene occurs usually 5 0 of exon 2, toward the centromere, in the first or second intron).
Candidate genes mapping by in silico methods
All sequence information within the minimal deleted region was complete and available through NCBI. Within this B120 kb of DNA, the following classes of ESTs were evaluated: (i) unique known genes such as RRP4; (ii) unknown sequences with homology to known genes such as PRDM12; and (iii) unique unknown genes, and predicted genes such as LOC158302, LOC138622 ( Figure 5 ). The relative merits and potential roles of these sequences in the causation of more aggressive CML disease phenotypes is discussed below.
Discussion
This study identified a high frequency of hemizygous microdeletions flanking the reciprocal rearranged ABL/BCR region of the der(9) in CML using Q-PCR methods. In keeping with previous FISH-based analysis of these rearrangements, 22, 24, 25 these deletions were also associated with adverse outcome, since all 25 samples with a microdeletion were identified in the subset of 71 CML patients with a less favorable treatment response. In contrast, none of the 18 CML patients with a favorable treatment response had a deletion. The improved mapping resolution, and ability of Q-PCR to detect microdeletions, allowed us to survey systematically the smaller genomic region immediately flanking the breakpoint region of the der(9) in 250 CML patients to identify deletions in 48 (B20%) samples either by FISH or by Q-PCR. This proportion of CML patients with deletions represents a significantly higher frequency than the 10-15% identified by conventional FISH methods alone. 22, 24, 25, 46 Q-PCR methods have been widely used for identifying genomic copy number changes, [26] [27] [28] [29] but have not previously been used to investigate microdeletions in the ABL/BCR region of the der(9) in CML. In this study, a series of 11 primer sets distributed across a region of 442 kb from BCR exon 17 to RH80328 on chromosome 22, and from ABL exon 1b to SHGC-143988 on chromosome 9 was used. Within this region, the distribution and relative frequency of microdeletions in CML were determined. Based on the expectation that a higher frequency of microdeletions would be present in the patients that responded poorly to treatment, a subset of 71 samples of the original 250 CML cases that had the most adverse outcome was selected for Q-PCR analysis. In every case, conventional FISH methods had excluded the possibility of a large submicroscopic deletion in ABL/BCR. 22 In this subset of 71 patients with adverse outcome, Q-PCR identified 25 (35%) patients with microdeletions. 
Figure 4
Identification of minimal deleted region 5 0 ABL on the der(9). Summary of the position of Q-PCR DNA copy number losses for all 25 CML patient samples, to determine the location of contiguous regions of deletion. Primers are listed on the Y-axis and the CML samples identified on the X-axis. The primer sets and CML samples with hemizygous deletion are indicated as white unfilled boxes. It can be seen that BCR is excluded from the minimal deleted region.
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The identification of frequent deletions in this region is consistent with previous RT-PCR analysis of ABL/BCR expression, which showed that B40% of CML do not express a detectable reciprocal fusion transcript. 47 It has been proposed that the primary mechanism for failure of ABL/BCR expression is often a direct consequence of translocation-dependent deletion events at der (9) . 48 In this model, the implicit assumption is that the minimal deleted region is situated in a central region defined by the ABL/BCR breakpoints. An alternative model, based on the most recent molecularclinical correlations 49, 50 and the Q-PCR mapping presented in this study, suggests that the minimal deleted region could actually be centered a few hundred kb away from the breakpoint regions of ABL. In a small subset of our samples it was possible to determine whether there was a deletion present in CML samples in which ABL/BCR was transcriptionally inactive. RT-PCR analysis showed that four CML samples did not express the ABL/BCR transcript. Of these, transcriptional inactivation was expected in three CML samples, since a hemizygous deletion of the 5 0 region of the ABL/BCR gene had already been identified. One CML sample without a deletion of the ABL/BCR gene did not express the reciprocal fusion transcript. For this sample, it is probable that expression was disrupted as a result of a more localized point or epigenetic mutation in the 5 0 region of ABL. Aberrant, inactivating methylation of the proximal promoter of the ABL gene has been previously reported. 51, 52 Recent studies concerning the clinical impact of the absence of the ABL/BCR fusion transcript in CML have been inconclusive. 53 Our findings, together with those of Huntly et al, 50 imply that some CML Ph translocations may have The minimal deleted region of the der(9) to indicate candidate genes in the B120 kb region centromeric to 5 0 ABL (NCBI map viewer, based on the genomi build at the time of writing). Sequences in this region such as PRDM12 may be recurrently subject to hemizygous deletion so that haploinsufficiency may have a role in the observed unfavorable outcome of CML patients with deletions.
Identification of minimal deleted region by QPCR E Kolomietz et al an associated epigenetic inactivation of the ABL/BCR transcript but do not have a deletion of the der (9) . If the primary determining factor associated with adverse prognosis in CML is a der(9) deletion in the region of ABL, then poor prognosis would not be expected to correlate per se with the absence of the ABL/BCR transcript. Thus, variation in epigenetic ABL inactivation associated with the translocation process may explain some of the inconclusive findings concerning correlation between loss of expression of ABL/BCR and clinical outcome in CML.
With the use of Q-PCR it is likely that it will be possible to determine whether there is an association between differential clinical responses to Imatinib and the presence or absence of microdeletion. Indeed, recently Huntly et al (American Society of Hematology Meeting, 2002; 100: 784a; Abstract #3098.) reported on a series of 276 patients, in varying stages of disease, treated with Imatinib. Of these, 14% (39/276) were found to carry a microdeletion by FISH analysis. No significant difference was found between those carrying the deletion and patients without an apparent deletion by FISH. Although this study includes a larger patient cohort, FISH analysis alone was used to identify deletions and thus a significant proportion of patients may carry a microdeletion that was undetected. Our recent ongoing analysis (in preparation) of 37 consecutive CML patients receiving Imatinib using Q-PCR and primers indicated above is showing a trend towards unfavorable cytogenetic response in the subset of five CML patients with a microdeletion. As such, it will be important to broaden the scope of all future Imatinib clinical trials to include a comprehensive evaluation of submicroscopic deletion in the region immediately adjacent to 5 0 ABL using Q-PCR and FISH methods.
The map of Q-PCR microdeletions of the der(9) shows that a smaller genomic region, extended for about 120 kb 5 0 to the ABL gene (the precise distance varies depending on the location of the breakpoints on the ABL gene), and flanked centromerically by the marker SHGC-141674, defined the minimal deleted region (see Figure 4) . It is noteworthy that deletions and loss of heterozygosity of the 9q34 region have previously been observed in a wide range of tumors, 54, 55 including leukemias, ovarian, bladder and lung cancers (Table 2) . Thus, it is conceivable that a tumor suppressor gene with a more general role in cancer may map to this location. Within this B120 kb region ( Figure 5 ), sequence analysis identified the following gene candidates: (i) RRP4, a known gene with 3 0 -5 0 -exoribonuclease activity; (ii) PRDM12, a PRdomain family member (discussed below); and (iii) LOC138622, which appears to be the human ortholog of mouse ribosomal protein L19.
The only known gene within this interval is the ribosomal RNA-processing 4-RRP4 gene, a 3 0 -5 0 exonuclease. [56] [57] [58] The three sequences LOC158302, and LOC138622 are hypothetical genes that did not contain evidence of conserved domains associated with function. The remaining candidate within the minimal deleted region is the PRDM12-PR-domain containing protein 12 gene. PRDM12 belongs to the PR (PRDI-BF1/Blimp-1 and RIZ homology) domain containing proteins that comprise a small family of zinc-finger-type DNA-binding transcription factors that appear to function as negative regulators of tumorigenesis. The predicted protein contains two main domains that define its function: (1) SET (PR)-domain of transcriptional regulators and (2) three C2H2 zinc-fingers. The SET-domain (Synonym(s): Suvar3-9, Trithorax) functions in chromatin-mediated gene expression. 59 The SET domain is a 130-amino acid, evolutionarily conserved sequence motif with histone methyltransferase activity, present in proteins that function in modulating gene activities from yeast to mammals. SET domain proteins are multifunctional chromatin regulators with activities in both eu-and heterochromatin. 59 It is noteworthy that haploinsufficiency has been proposed as a model to explain the more aggressive phenotype of homozygous knockouts of the best studied member of the PRDM gene family, RIZ1. 60 Thus, PRDM12 is probably the strongest candidate tumor suppressor gene mapping to the minimal deleted region with a potential role in CML outcome. More extensive phenotype-genotype correlative studies of CML with deletions using Q-PCR will help determine the gene or genes recurrently subject to haploinsufficiency and having a role in unfavorable prognosis. Table 2 Neoplasms associated with deletions of the 9q (34) [64] [65] [66] Deletions and translocations at 9(q34) Ovarian cancer [67] [68] [69] Deletions at 9q ( 
